Jupiter Topco LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Jupiter Topco LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 144,821 shares of the biopharmaceutical company’s stock, valued at approximately $90,310,000.

Other hedge funds have also modified their holdings of the company. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $26,000. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Finally, Birchwood Financial Partners Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock worth $1,090,030 over the last 90 days. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Despite the setback, Wall Street remains generally constructive on Regeneron’s long-term growth prospects, and the shares have outperformed the broader S&P 500 over the past year. The company’s latest reported quarter also showed strong execution, with revenue up 16.7% year over year and EPS substantially above consensus estimates. Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: A reported August short-interest update showed zero shares sold short, but the figures appear incomplete or erroneous because the reported change was listed as “NaN.” It therefore provides little reliable information about current trading sentiment.
• Negative Sentiment: Several law firms announced or promoted a securities class action alleging that Regeneron misled investors about the viability and prospects of the Phase 3 Fianlimab-Libtayo melanoma study, including by emphasizing earlier-stage results and practice-changing expectations. The allegations have not been proven, but the litigation adds reputational, financial, and uncertainty-related overhang. Investors who purchased shares between August 1, 2025, and May 15, 2026, are being reminded of a September 14, 2026, deadline to seek lead-plaintiff status. Regeneron Investors: September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals Trading Down 2.3%

Shares of REGN opened at $814.79 on Thursday. The stock’s 50-day moving average is $709.88 and its two-hundred day moving average is $717.69. The stock has a market cap of $83.89 billion, a PE ratio of 20.14, a P/E/G ratio of 1.42 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $847.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue was up 16.7% on a year-over-year basis. During the same period last year, the business posted $12.81 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on REGN shares. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Barclays cut their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Finally, Truist Financial raised their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a report on Friday, July 31st. Fifteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $800.36.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.